# Comparative Cycle Control Europe

> **NCT00185367** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 798 (actual)

## Conditions studied

- Contraception

## Interventions

- **DRUG:** EV/DNG (Qlaira, BAY86-5027, SH T00658K)
- **DRUG:** SH D 593 B (Miranova)

## Key facts

- **NCT ID:** NCT00185367
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** —
- **Final completion:** 2006-09
- **Target enrollment:** 798 (ACTUAL)
- **Last updated:** 2011-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00185367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00185367, "Comparative Cycle Control Europe". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00185367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*